Stem Cell Research for Melanoma and Head and Neck Cancer
Recruiting in Palo Alto (17 mi)
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: University of Colorado, Denver
No Placebo Group
Approved in 4 Jurisdictions
Trial Summary
What is the purpose of this trial?
The overall goal of this study is to develop a pre-clinical platform of melanoma and head and neck squamous cell cancer that will allow the investigators to learn more about these diseases and discover better and more individualized treatments.
Research Team
Antonio Jimeno, MD, PhD
Principal Investigator
University of Colorado, Denver
Eligibility Criteria
This trial is for adults over 21 with incurable melanoma or head and neck squamous cell cancer (HNSCC) that can be biopsied. Participants must have a performance status of 0-2, meaning they are fully active to limited in physical activity but able to care for themselves. They need normal bone marrow, liver, and kidney function, measurable disease by certain criteria, and good oxygen levels without assistance.Inclusion Criteria
I can take care of myself and am up and about more than half of my waking hours.
Your blood, liver, and kidney functions are at normal levels. You have enough red and white blood cells, and your organs are working well. You have measurable disease according to specific criteria, and you can understand and agree to sign a consent form.
I have melanoma or head/neck cancer that cannot be cured, but can be biopsied or surgically removed at the University of Colorado Hospital.
See 1 more
Exclusion Criteria
I don't have allergies to E. coli proteins, sickle cell, severe lung disease, significant spleen issues, active cancer other than melanoma or head/neck cancer, or hepatitis B/C or HIV.
Treatment Details
Interventions
- Filgrastim (Hematopoietic Stem Cell Mobilizer)
Trial OverviewThe study is testing the use of Filgrastim—a medication that promotes white blood cell growth—to develop a pre-clinical model for melanoma and HNSCC. This will help understand these cancers better and find more personalized treatments.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Melanoma, head and neckExperimental Treatment1 Intervention
10 μg/kg/day of Filgrastim will be given subcutaneously for 4 days
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Colorado, Denver
Lead Sponsor
Trials
1,842
Recruited
3,028,000+
Aviva Abosch
University of Colorado, Denver
Chief Medical Officer since 2019
MD
Uday B. Kompella
University of Colorado, Denver
Chief Executive Officer since 2015
PhD in Pharmaceutical Sciences
Karsh Family Research Fund
Collaborator
Trials
1
Recruited
9+
Karsh Family Research Fund
Collaborator
Trials
1
Recruited
9+